KNSA FY 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M

Gross Profit

$29M76.4% margin

Operating Income

-$157M-406.4% margin

Net Income

-$158M-409.7% margin

EPS (Diluted)

$-2.30

Cash Flow

Operating Cash Flow

-$126M

Free Cash Flow

-$147M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$233M

Total Liabilities

$48M

Stockholders' Equity

$185M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$0	—
Gross Profit	$29M	-$4M	+873.8%
Operating Income	-$157M	-$157M	+0.5%
Net Income	-$158M	-$161M	+2.1%